Company intelligence / Profile preview

FLAG Therapeutics

Raleigh, North Carolina, United Statesflagtherapeutics.com ↗

Ownership: Private
Employees: ~3
Development stage: Other

Overview

FLAG Therapeutics develops novel, water-soluble small molecule drugs with dual mechanisms of action for difficult-to-treat cancers. Their lead candidate, FLAG‑003, has shown promising preclinical results against DIPG and GBM and has received rare pediatric disease designation as well as orphan drug designation. The company holds a robust IP portfolio (>100 issued patents) and expects to initiate first-in-human trials in early 2025.

Therapeutic areas: Oncology
Modalities: Small molecules (including dual-action/dual-targeting small molecules)
Industry: Biotech

Drug pipeline

3 assets

FLAG-003

Preclinical

2 more assets in the full pipeline.

Partnerships

Exclusive worldwide licensing agreement with Duquesne University for two classes of small molecules and ongoing discoveries from Dr. Aleem Gangjee’s lab. No major pharma partnerships disclosed.

Beyond the preview

Go deeper on FLAG Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FLAG Therapeutics.